“LYMPHIR is an important new treatment option for the CTCL community, and its launch marks the beginning of a new chapter for ...

JAK2 gene fusion appears across multiple CTCL types, shaping diagnosis and treatment opportunities. Learn more about its ...

Citius Oncology (CTOR) said on Monday it has launched Lymphir, a newly approved cancer immunotherapy for adults with relapsed ...

Citius Oncology launches US FDA approved Lymphir, a novel cancer immunotherapy for cutaneous T-cell lymphoma: Cranford, New Jersey Wednesday, December 3, 2025, 16:00 Hrs [IST] Cit ...

The US Food and Drug Administration has approved denileukin diftitox-cxdl (Lymphir, Citius Pharmaceuticals) for adults with relapsed or refractory stage 1-3 cutaneous T-cell lymphoma after at least ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab-treated patients with AD were 4.1003 times more likely to develop cutaneous T-cell lymphoma vs. those ...

Please provide your email address to receive an email when new articles are posted on . HyBryte is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. Three of ...

The global T-Cell lymphoma therapeutics market size was valued at US$ 2.3 Bn in 2024 and is projected to reach US$ 5.7 Bn by ...

Cutaneous T cell lymphomas (CTCL) represent a heterogeneous group of T-cell malignancies that manifest primarily in the skin. By far the most common variant of CTCL is mycosis fungoides and its ...